Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.

scientific article published on 02 June 2017

Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/S1470-2045(17)30429-1
P932PMC publication ID5991615
P698PubMed publication ID28592387

P50authorLaurent MortierQ58300362
Luc ThomasQ61182298
Ivan Marquez-RodasQ63958350
Vanna Chiarion SileniQ72848421
Nicolas MeyerQ85215679
Ana AranceQ42645931
Georgina V. LongQ42947998
P2093author name stringYing Zhang
Keith T Flaherty
Stergios J Moschos
Caroline Robert
David Hogg
Céleste Lebbé
Michael A Davies
Jean-Jacques Grob
Philippe Saiag
Thierry Lesimple
Bijoyesh Mookerjee
Michele Del Vecchio
Yingjie Huang
P2860cites workDabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trialQ44442912
Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.Q45974368
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trialQ48594003
Prognostic factors for survival in melanoma patients with brain metastasesQ85226494
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutationsQ24632064
Improved overall survival in melanoma with combined dabrafenib and trametinibQ27853091
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaQ29615443
Pembrolizumab versus Ipilimumab in Advanced MelanomaQ29618134
Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trialsQ31143336
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trialQ33926135
Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic targetQ34438536
Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot studyQ34658082
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanomaQ34664981
Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical featuresQ37036930
Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastasesQ37231972
Multidisciplinary approach to brain metastasis from melanoma: the emerging role of systemic therapiesQ38110085
Determinants of outcome in melanoma patients with cerebral metastasesQ38517839
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 studyQ38802138
Melanoma central nervous system metastases: current approaches, challenges, and opportunitiesQ38807942
The mitogen-activated protein kinase pathway in melanoma part I - Activation and primary resistance mechanisms to BRAF inhibition.Q39124064
Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trialQ39537308
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trialQ40875359
Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma.Q41675125
P433issue7
P921main subjectmulticenter clinical trialQ6934595
phase II clinical trialQ42824440
P304page(s)863-873
P577publication date2017-06-04
P1433published inLancet Oncology CommissionQ13747613
P1476titleDabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
P478volume18

Reverse relations

cites work (P2860)
Q57818351A new B-Raf inhibitor combo for advanced melanoma
Q47375181Advanced Melanoma: Current Treatment Options, Biomarkers, and Future Perspectives.
Q91646745Analysis of the Whole-Exome Sequencing of Tumor and Circulating Tumor DNA in Metastatic Melanoma
Q90084242Are we AKT-ually getting closer to making targeted therapy successful in breast cancer brain metastases?
Q47573009BRAF-MEK inhibition in melanoma brain metastases: a new hope
Q52318443Brain Metastases in Oncogene-Addicted Non-Small Cell Lung Cancer Patients: Incidence and Treatment
Q91099817Brain metastases
Q89647087CIC Mutation as a Molecular Mechanism of Acquired Resistance to Combined BRAF-MEK Inhibition in Extramedullary Multiple Myeloma with Central Nervous System Involvement
Q88486186Cancérologie cutanée et psoriasis
Q52618227Changing the standard of care for treating melanoma brain metastases
Q91267174Choice of first-line therapy in metastatic melanoma
Q96428151Clinical Development of BRAF plus MEK Inhibitor Combinations
Q52618225Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study
Q90711858Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients
Q91832432Comprehensive Clinical Trial Data Summation for BRAF-MEK Inhibition and Checkpoint Immunotherapy in Metastatic Melanoma
Q98226267Current State of Target Treatment in BRAF Mutated Melanoma
Q89811416Current approaches to the management of brain metastases
Q49357054Current aspects in the prognosis of advanced melanoma
Q92872909Current multidisciplinary management of brain metastases
Q42691126Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.
Q56673276Deciphering mechanisms of brain metastasis in melanoma - the gist of the matter
Q100568729Down-regulation of Aquaporin-1 mediates a microglial phenotype switch affecting glioma growth
Q89855148Drug Development for Central Nervous System Diseases Using In Vitro Blood-brain Barrier Models and Drug Repositioning
Q47573654Drug delivery to melanoma brain metastases: Can current challenges lead to new opportunities?
Q99709326Effectiveness and Safety of Dabrafenib in the Treatment of 20 Chinese Children with BRAFV600E-Mutated LCH
Q92859532Empiric Therapy with BRAF and MEK Inhibitors in Metastatic Melanoma
Q55000567Expression Differentiation Is Not Helpful in Identifying Prognostic Genes Based on TCGA Datasets.
Q64256452Factors influencing the outcome of stereotactic radiosurgery in patients with five or more brain metastases
Q92336270Feasibility study of using high-throughput drug sensitivity testing to target recurrent glioblastoma stem cells for individualized treatment
Q56889910Focal radiation necrosis of the brain in patients with melanoma brain metastases treated with pembrolizumab
Q94076885Highlights from the Literature
Q94387525Highlights from the Literature
Q47145423Identification of coexistence of BRAF V600E mutation and EZH2 gain specifically in melanoma as a promising target for combination therapy
Q41324789Identification of prognostic genes through expression differentiation during metastatic process in lung adenocarcinoma.
Q93088315Immune Microenvironment of Brain Metastases-Are Microglia and Other Brain Macrophages Little Helpers?
Q92524861Incidence, patterns of progression, and outcomes of preexisting and newly discovered brain metastases during treatment with anti-PD-1 in patients with metastatic melanoma
Q64057768Inhibition of mitochondrial respiration prevents BRAF-mutant melanoma brain metastasis
Q64093580Innovative Therapeutic Strategies for Effective Treatment of Brain Metastases
Q90971217Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series
Q89987318Long-Term Outcomes in BRAF-Mutated Melanoma Treated with Combined Targeted Therapy or Immune Checkpoint Blockade: Are We Approaching a True Cure?
Q58582837Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial
Q64971747Management of metastatic cutaneous melanoma: updates in clinical practice.
Q58547833Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma
Q98467275Medical management of brain metastases
Q91610930Melanoma
Q50125923Melanoma Brain Metastases: Local Therapies, Targeted Therapies, Immune Checkpoint Inhibitors and Their Combinations-Chances and Challenges.
Q47379314Melanoma brain metastases harboring BRAF V600K or NRAS mutations are associated with an increased local failure rate following conventional therapy
Q47227422Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells
Q56890594Metastatic Melanoma: Recent Therapeutic Progress and Future Perspectives
Q91759638Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases
Q98467276Multidisciplinary patient-centered management of brain metastases and future directions
Q91280474Neurologic complications of melanoma
Q97556545Neurological symptom burden impacts survival prognosis in patients with newly diagnosed non-small cell lung cancer brain metastases
Q64326768New developments in brain metastases
Q55005503ORAL DRUG THERAPY - IMPROVING SURVIVAL IN MALIGNANT MELANOMA.
Q90376945Operative and peri-operative considerations in the management of brain metastasis
Q96953882Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations
Q89964967PET/MRI Radiomics in Patients With Brain Metastases
Q91462143PLEKHA5 regulates tumor growth in metastatic melanoma
Q92293389Perilesional edema in brain metastases: potential causes and implications for treatment with immune therapy
Q92086166Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th-1 December 1st, 2018, Naples, Italy)
Q48122257Primary medical therapy for BRAFV600E-mutant melanoma brain metastases-is this good enough?
Q48122251Primary medical therapy for BRAFV600E-mutant melanoma brain metastases-is this good enough? - Authors' reply
Q92137764Profound MEK inhibitor response in a cutaneous melanoma harboring a GOLGA4-RAF1 fusion
Q92916545Prognostic assessment in patients with newly diagnosed small cell lung cancer brain metastases: results from a real-life cohort
Q58563207Pseudoprogression of Melanoma Brain Metastases
Q59341081Recent advances in managing brain metastasis
Q52690028Recent advances in therapeutic strategies for unresectable or metastatic melanoma and real-world data in Japan
Q64898821Regression of BRAF V600E mutant adult glioblastoma after primary combined BRAF-MEK inhibitor targeted therapy: a report of two cases.
Q55002911Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2.
Q90080013Significance of BRAF Kinase Inhibitors for Melanoma Treatment: From Bench to Bedside
Q94458869Solitary metastatic melanoma of the pituitary gland: Report of two cases and Literature review
Q64055641Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity
Q89720725Stereotactic radiosurgery combined with targeted/ immunotherapy in patients with melanoma brain metastasis
Q57816905Strategies to Preserve Cognition in Patients With Brain Metastases: A Review
Q90481686Supportive roles of brain macrophages in CNS metastases and assessment of new approaches targeting their functions
Q54997408Survival and clinical outcomes of patients with melanoma brain metastasis in the era of checkpoint inhibitors and targeted therapies.
Q47185289Survival and prognostic factors for patients with melanoma brain metastases in the era of modern systemic therapy.
Q92255269Systemic therapy for brain metastases
Q49956245Targeted therapy of brain metastases: latest evidence and clinical implications
Q91326756Targeted therapy: a potential oversight in trial protocol
Q64067749Targeting Molecular Pathways in Intracranial Metastatic Disease
Q52673453The Evolving Landscape of Brain Metastasis.
Q99402160The Role of Stereotactic Biopsy in Brain Metastases
Q92888273The Systemic Treatment of Melanoma
Q47247953The biology and therapeutic management of melanoma brain metastases
Q90474060The impact of current treatment modalities on the outcomes of patients with melanoma brain metastases: A systematic review
Q91709281The impact of systemic precision medicine and immunotherapy treatments on brain metastases
Q91740514The impact of targeted therapies and immunotherapy in melanoma brain metastases: A systematic review and meta-analysis
Q47105677The significance of BRAF V600E mutation status discordance between primary cutaneous melanoma and brain metastases: The implications for BRAF inhibitor therapy
Q90304141Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1-based therapy
Q90482925Trifluoperazine prolongs the survival of experimental brain metastases by STAT3-dependent lysosomal membrane permeabilization
Q56890934Update on systemic therapy for advanced cutaneous melanoma and recent development of novel drugs
Q49715996What's new in oncodermatology?
Q47899183Whole-Brain Radiotherapy for Brain Metastases: Evolution or Revolution?
Q90614401[Malignant melanoma]

Search more.